Should You Buy AbbVie Stock Hand Over Fist Before April 29?

AbbVie reports Q1 earnings on April 29, with the market focused on whether Skyrizi and Rinvoq can deliver strong growth and offset continued Humira decline and weaker Imbruvica sales. The article highlights projected first-quarter net revenue of $14.7 billion, about 10% year-over-year growth, while noting upside could depend on guidance and clinical or regulatory updates. Despite near-term uncertainty, AbbVie’s 54-year dividend growth streak is cited as a long-term support for the stock.

Analysis

ABBV is a classic “good business, awkward stock” setup: the equity may not rerate on the quarter unless the market gets proof that post-Humira mix shift is broadening, not just masking erosion elsewhere. The key second-order issue is that investors are paying for de-risking of the earnings bridge; if the growth pillars look strong but the legacy franchises decay faster, the market will likely treat that as a net quality deterioration rather than an absolute beat. That makes the print more about composition than headline EPS.

The asymmetry is that downside can be sharp in the next 1-3 trading sessions if guidance implies any pause in the Skyrizi/Rinvoq ramp or a steeper-than-expected drag from Imbruvica and Humira. But over a 6-12 month horizon, the dividend and cash generation should cap valuation compression unless management signals a structural problem in the 2025-26 growth trajectory. In other words: short-term multiple risk is real; medium-term fundamental solvency risk is not.

The contrarian angle is that the market may be underestimating how much of ABBV’s valuation is already anchored to income investors who care more about payout durability than quarter-to-quarter franchise mix. That tends to reduce the odds of a sustained selloff after a merely decent print. The bigger mispricing may be in relative performance: if ABBV clears the guide without raising long-term anxiety, the stock can outperform low-quality defensives and highly valued growth names on a risk-adjusted basis, even if absolute upside is modest.

Key Decisions for Investors

• Go long ABBV into the print only via limited-risk structure: buy 1-2 month call spreads or a small equity starter position, targeting a 5-8% upside move if guidance validates the 2025-26 growth bridge; cap downside at ~3-4% premium paid or a tight stop if legacy revenue commentary worsens.
• If already long ABBV, hedge event risk with short-dated puts or a collar through earnings; the setup favors muted upside beyond a clean beat, but there is meaningful 1-day gap risk if management sounds cautious on franchise mix.
• Relative-value trade: long ABBV / short a basket of slower-growth large-cap pharma with weaker dividend support over the next 1-3 months; ABBV should command a premium if it proves it can sustain mid-teens growth while legacy assets decline.
• Avoid chasing the stock if it rallies on the print without a raised medium-term outlook; that move would likely be dividend-income buying rather than a fundamental reset, leaving limited follow-through over the next 4-8 weeks.
• For long-only portfolios, keep ABBV as a defensive income sleeve rather than a catalyst trade; expected total return is driven more by yield plus low-teens fundamental compounding than by earnings-day alpha.